MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ANIP Stock surged +2.02% Today — RQD Quant Desk Flash
$73.16 +2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $73.60
ANI Pharmaceuticals Inc. (ANIP) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (steady margins, 16% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $1.68B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $73.60 (+0.60%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 19.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANIP)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY ANIP SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 19.4% FCF Margin ($171.4M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade A-$73.89-2.2% Next Q
78
Q2 (-2Q)Grade B+$72.29+0.4% Next Q
75
Q3 (-1Q)Grade B$72.61+0.8% Next Q
73
CurrentGrade B-$73.16+6.6% Hist 90D α
70
Trajectory: A- (78) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the ANIP Bull Thesis Could Fail
Even with a 70/100 (B-) score, ANIP faces multiple-compression risk if 21.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.95) or 200D SMA ($77.65) invalidates the momentum regime and cuts Target Base ($77.11) toward Bear Floor ($59.99).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANIP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANIP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ANIP Stock surged +2.02% Today — RQD Quant Desk Flash
ANI Pharmaceuticals Inc. (ANIP) surged +2.02% to $73.16, trading at 14% of its 52-week range ($69.58 – $95.57). High-quality cash engine (steady margins, 16% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 14% of its 52-week range ($69.58 – $95.57) with RSI-14 at 47.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.7% around $73.16 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 52% gross margin and $171.4M annual free cash flow.
Live ANIP Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (ANIP Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ANIP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.92%▼ DESCENDING CHANNEL
2026-10-30O $73.27H $73.54L $71.90C $73.16VOL 286.9K
RES: $75.18SUP: $64.27SMA50: $72.95SMA200: $77.65
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ANIP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
15.2%/yr Implied 5Y Growth
vs. +43.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ANIP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ANIP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANIP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIP)
Health Care Rank #92 of 1016
⚔️ NUVB vs ANIP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ANIP vs. NUVB, CMPS, STOK, RARE)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ANI Pharmaceuticals Inc. (ANIP) ranks #92 by composite RQD confidence (70/100, grade B-) and #289 by equity capitalization ($1.68B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANIP
ACTIVE
ANI Pharmaceuticals Inc. | B- | 70/100 | 21.5x | — | 16.0% | +2.02% | $1.68B | Benchmark Subject |
| NUVB Nuvation Bio Inc. (Class A) | E | 29/100 | — | — | -35.0% | +3.92% | $1.67B | /nuvb-vs-anip → |
| CMPS COMPASS Pathways Plc American Depository Shares | D- | 37/100 | — | — | -35.0% | -0.73% | $1.69B | /cmps-vs-anip → |
| STOK Stoke Therapeutics Inc. | C- | 59/100 | — | — | -6.1% | -0.23% | $1.70B | /stok-vs-anip → |
| RARE Ultragenyx Pharmaceutical Inc. | E | 26/100 | — | — | -35.0% | -2.44% | $1.65B | /rare-vs-anip → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001023024In its most recent audited fiscal period (FY2025, filed 2025-12-31), ANI Pharmaceuticals Inc. (ANIP) reported GAAP revenue of $883.4M (+43.8% vs. FY2024 revenue of $614.4M , and +81.5% cumulative change since FY2023) , GAAP net income of $78.0M, operating cash flow of $185.2M, and free cash flow of $171.4M (+258.7% YoY). On the balance sheet, ANIP closed FY2025 with $1.44B in total assets against $291.8M in total debt (Altman Z-Score: 2.36, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $883.4M | $78.0M | $185.2M | $171.4M | $1.44B | $291.8M |
| FY2024 (FY) | 2024-12-31 | $614.4M | -$19.0M | $64.0M | $47.8M | $1.28B | $309.1M |
| FY2023 (FY) | 2023-12-31 | $486.8M | $19.0M | $119.0M | $119.0M | — | — |
3. ANIP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ANIP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, ANI Pharmaceuticals Inc. (NASDAQ: ANIP) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $73.16 (+2.02% 1D, market cap $1.68B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, ANIP ranks #92 in composite RQD confidence.
How does ANIP compare to NUVB and CMPS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIP carries a Roarable B- (70/100 RQD), trailing P/E of 21.5x, gross margin of —, and ROIC of 16.0%. By comparison, NUVB (Nuvation Bio Inc. (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and CMPS (COMPASS Pathways Plc American Depository Shares) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.69B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ANIP?
Per ANIP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001023024), ANI Pharmaceuticals Inc. generated $883.4M in revenue (+43.8% YoY), $78.0M in net income, and $171.4M in free cash flow against $1.44B in total assets and $291.8M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ANIP trading relative to its 50-day, 200-day, and 52-week technical levels?
ANIP last traded at $73.16 (+2.02% on volume of 262,430 shares), positioning the stock +0.29% above its 50-day simple moving average ($72.95) and -5.78% below its 200-day simple moving average ($77.65). Across its 52-week range of $69.58 to $95.57, ANIP sits at the 13.8% percentile with a 14-day RSI of 47.2 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($68.99 to $77.33).
ANIP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ANIP stock moving today?
Why ANIP Stock surged +2.02% Today — RQD Quant Desk Flash. High-quality cash engine (steady margins, 16% return on capital) with steady institutional support.